Abstract
Human kinases are one of the most promising targets for cancer therapy. Methods able to measure the effects of drugs on these cell agents remain crucial for biologists and medicinal chemists. The current work therefore sought to develop an in-capillary enzymatic assay based on capillary electrophoresis (CE) to evaluate the inhibition of phosphatidylinositol-3-kinase (PI3K), protein kinase B (Akt), and the mammalian target of rapamycin (mTOR). These kinases belong to the same signaling pathway PI3K/Akt/mTOR. For this proposal, the capillary was used as a nanoreactor in which a few nanoliters of the kinase, its substrate, adenosine triphosphate (ATP), and the potent inhibitor were separately injected. A transverse diffusion of laminar flow profiles (TDLFP) approach was employed to mix the reactants. Adenosine diphosphate (ADP ) was detected online at 254 nm. The CE assay was first developed on the α isoform of PI3K. It was compared to five commercial kits frequently used to assess kinase inhibition, based on time-resolved fluorescence resonance energy transfer (TR-FRET) and bioluminescence. Each assay was evaluated in terms of sensitivity (S/B), reproducibility (Z′), and variability (r 2). This CE method was easily extended to assay the inhibition of the β, γ, and δ isoforms of PI3K, and of the other kinases of the pathway, Akt1 and mTOR, since it is based on in-capillary mixing by TDLFP and on ADP quantification by simple UV absorption. This work shows for the first time the evaluation of inhibitors of the kinases of the PI3K/Akt/mTOR pathway using a common in-capillary CE assay. Several inhibitors with a wide range of affinity toward these enzymes were tested.
Similar content being viewed by others
References
Hirsch E, Katanaev VL, Garlanda C, Azzolino O, Pirola L, Silengo L, Sozzani S, Mantovani A, Altruda F, Wymann MP (2000) Science 287:1049–1053
Jackson SP, Schoenwaelder SM, Goncalves I, Nesbitt WS, Yap CL, Wright CE, Kenche V, Anderson KE, Dopheide SM, Yuan Y, Sturgeon SA, Prabaharan H, Thompson PE, Smith GD, Shepherd PR, Daniele N, Kulkarni S, Abbott B, Saylik D, Jones C, Lu L, Giuliano S, Hughan SC, Angus JA, Robertson AD, Salem HH (2005) Nat Med 11:507–514
Ali K, Bilancio A, Thomas M, Pearce W, Gilfillan AM, Tkaczyk C, Kuehn N, Gray A, Giddings J, Peskett E, Fox R, Bruce I, Walker C, Sawyer C, Okkenhaug K, Finan P, Vanhaesebroeck B (2004) Nature 431:1007–1011
Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K (2011) Cancer Res 71:154–163
Zhou Q, Lui VWY, Yeo W (2011) Future Oncol 7:1149–1167
Krylova SM, Okhonin V, Evenhuis CJ, Krylov SN (2009) Trends Anal Chem 28:987–1010
Nehmé H, Nehmé R, Lafite P, Routier S, Morin P (2012) Anal Chim Acta 722:127–135
Hai X, Yang B-f, Van Schepdael A (2012) Electrophoresis 33:211–227
Suresh Babu CV, Cho SG, Yoo YS (2005) Electrophoresis 26:3765–3772
Nehmé H, Nehmé R, Lafite P, Duverger E, Routier S, Morin P (2013) Anal Bioanal Chem 405:9159–9167
Nehmé H, Nehmé R, Lafite P, Routier S, Morin P (2013) J Sep Sci 36:2151–2157
Nehmé H, Nehmé R, Lafite P, Routier S, Morin P (2013) J Chromatogr A 1314:298–305
Nehmé R, Nehmé H, Roux G, Destandau E, Claude B, Morin P (2013) J Chromatogr A 1318:257–264
Yoon S, Ban E, Yoo YS (2002) J Chromatogr A 976:87–93
Nam H-S, Ban E, Yoo E, Yoo YS (2002) J Chromatogr A 976:79–85
Huang W, Jiang D, Wang X, Wang K, Sims CE, Allbritton NL, Zhang Q (2011) Anal Bioanal Chem 401:1881–1888
Jiang D, Sims CE, Allbritton NL (2011) Faraday Disc 149:187–200
Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM (2002) Cancer Res 62:1401–1409
Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang S-Y, Robell K, Kahana JA, Geske RS, Kleymenova EV, Choudhry AE, Lai Z, Leber JD, Minthorn EA, Strum SL, Wood ER, Huang PS, Copeland RA, Kumar R (2008) Cancer Res 68:2366–2374
Saurat T (2012) Synthèse d'inhibiteurs pyridopyrimidiniques de la voie PI3k/Akt/mTOR et mise au point des tests enzymatiques dans l'évaluation de leurs activités inhibitrices. Université d'Orléans, Orléans
Yan L. AACR Annual Meeting 2009: Abstract number: DDT01-1
Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM (2006) Cell 125:733–747
Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y (1993) J Biol Chem 268:25846–25856
Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Grønning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR (2007) Biochem J 404:449–458
Maira S-M, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C (2008) Mol Cancer Ther 7:1851–1863
Mercado N, To Y, Ito K, Barnes PJ (2011) J Pharmacol Exp Ther 337:465–470
Klink T, Kleman-Leyer K, Kopp A, Westermeyer T, Lowery R (2008) J Biomol Screen 13:476–485
Stankewicz C, Rininsland FH (2006) J Biomol Screen 11:413–422
Nehmé R, Perrin C (2013) Highly charged polyelectrolyte coatings to prevent adsorption during protein and peptide analysis in capillary electrophoresis, capillary electrophoresis of biomolecules, vol 984. Methods in molecular biology. Humana Press, Germany, pp 191–206. doi:10.1007/978-1-62703-296-4_14
Nehmé R, Perrin C, Cottet H, Blanchin M-D, Fabre H (2009) Electrophoresis 30:1888–1898
Nehmé R, Perrin C, Cottet H, Blanchin MD, Fabre H (2011) J Chromatogr A 1218:3537–3544
Okhonin V, Liu X, Krylov SN (2005) Anal Chem 77:5925–5929
Zhang JH, Chung T, Oldenburg K (1999) J Biomol Screen 4:67–73
Kupcho K, Stafslien D, Singh U, Eliason H, Reichling L, Frazee W, Horton R, Riddle S, Yi Gao Y. The Adapta™ universal kinase assay: a superior alternative to luciferase-based kinase assays. Poster available online at http://tools.invitrogen.com/content/sfs/posters/0108-Adapta-poster-comparison-to-Kinase-Glo.pdf. Accessed 7 Oct 2013
Carpenter C, Duckworth B, Auger K, Cohen B, Schaffhausen B, Cantley L (1990) J Biol Chem 265:19704–19711
Gray A, Olsson H, Batty IH, Priganica L, Peter Downes C (2003) Anal Biochem 313:234–245
Nehmé R, Perrin C, Cottet H, Blanchin MD, Fabre H (2008) Electrophoresis 29:3013–3023
Arrio-Dupont M, Cribier S, Foucault G, Devaux PF, Albis A (1996) Biophys J 70:2327–2332
Kaiser TJ, Thompson JW, Mellors JS, Jorgenson JW (2009) Anal Chem 81:2860–2868
Okhonin V, Petrov AP, Krylova SM, Krylov SN (2011) Angew Chem 123:12205–12208
Krylova SM, Okhonin V, Krylov SN (2009) J Sep Sci 32:742–756
Badinloo M, Esmaeili-Mahani S (2013) Fundam Clin Pharmacol. doi:10.1111/fcp.12043
Gill I (2001) Chem Mater 13:3404–3421
Lindsley CW, Barnett SF, Layton ME, Bilodeau MT (2012) Curr Cancer Drug Targets 8:7–18
Banham-Hall E, Clatworthy M, Okkenhaug K (2012) Open Rheumatol J 6:245–258
Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT (2007) Mol Cancer Ther 6:2505–2514
Acknowledgments
This work was supported by “La Ligue Nationale contre le Cancer, Comité du Loiret”, the “Conseil Régional du Centre”, and the “Cancéropôle Grand-Ouest”. Thibault Saurat was the recipient of an INCa/Région Centre PhD fellowship. We are very grateful to Pr. Philippe Bougnoux for his constant support and encouragement.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
PDF 51.4 kb
Rights and permissions
About this article
Cite this article
Nehmé, R., Nehmé, H., Saurat, T. et al. New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway. Anal Bioanal Chem 406, 3743–3754 (2014). https://doi.org/10.1007/s00216-014-7790-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-014-7790-z